Cybin applauds fda commissioner dr. martin makary's call to accelerate and prioritize research on psychedelic therapeutics

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent comments made by dr. martin makary, commissioner of the u.s. fda relating to the importance of accelerating and prioritizing research on the clinical benefits of psychedelic therapeutics. “it is gratifying that th.
CYBN Ratings Summary
CYBN Quant Ranking